Rapid analysis of angiogenesis drugs in a live fluorescent zebrafish assay [1]

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 5, 2003, Pages 911-912

  Cross, Laura M ^a   Cook, Marisa A ^a   Lin, Shuo ^a,b   Chen, Jau Nian ^b   Rubinstein, Amy L ^a  

^a Zygogen LLC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; GREEN FLUORESCENT PROTEIN; SEMAXANIB; VASCULOTROPIN RECEPTOR 2; VATALANIB;

ANGIOGENESIS; ANIMAL CELL; CANCER THERAPY; DRUG RECEPTOR BINDING; DRUG SCREENING; EMBRYO; FLUORESCENCE; HUMAN; LETTER; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; ZEBRA FISH;

ANGIOGENESIS INHIBITORS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BIOLOGICAL ASSAY; BIOLOGICAL MARKERS; DRUG EVALUATION, PRECLINICAL; EMBRYO, NONMAMMALIAN; FLUORESCENT DYES; LUMINESCENT PROTEINS; NEOVASCULARIZATION, PHYSIOLOGIC; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; ZEBRAFISH;

EID: 0038639367     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000068685.72914.7E     Document Type: Letter

References (25)

1. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-364.
2. Li CY, Shan S, Cao Y, Dewhirst MW. Role of incipient angiogenesis in cancer metastasis. Cancer Met Rev. 2000;19:7-11.
3. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249-257.
4. Rosen L. Antiangiogenic strategies and agents in clinical trials. Oncologist. 2000;5(Suppl 1):20-27.
5. Isogai S, Horiguchi M, Weinstein BM. The vascular anatomy of the developing zebrafish: an atlas of embryonic and early larval development. Dev Biol. 2001;230:278-301.
6. Vogel AM, Weinstein BM. Studying vascular development in the zebrafish. Trends Cardiovasc Med. 2000;10:352-360.
7. Chan J, Bayliss PE, Wood JM, Roberts TM. Dissection of angiogenic signaling in zebrafish using a chemical genetic approach. Cancer Cell. 2002;1:257-267.
8. Serbedzija GN, Flynn E, Willett CE. Zebrafish angiogenesis: a new model for drug screening. Angiogenesis. 1999;3:353-359.
9. Fouquet B, Weinstein BM, Serluca FC, Fishman MC. Vessel patterning in the embryo of the zebrafish: guidance by notochord. Dev Biol. 1997; 183:37-48.
10. Liao W, Bisgrove BW, Sawyer H, Hug B, Bell B, Peters K, Grunwald DJ, Stainier DY. The zebrafish gene cloche acts upstream of a flk-1 homologue to regulate endothelial cell differentiation. Development. 1997;124:381-389.
11. Weinstein BM, Stemple DL, Driever W, Fishman MC. Gridlock, a localized heritable vascular patterning defect in the zebrafish. Nat Med. 1995;1:1143-1147.
12. Motoike T, Loughna S, Perens E, Roman BL, Liao W, Chau TC, Richardson CD, Kawate T, Kuno J, Weinstein BM, Stainier DYR, Sato TN. Universal GFP reporter for the study of vascular development. Genesis. 2000;28:75-81.
13. Lawson ND, Weinstein BM. In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev Biol. 2002;248:307-318.
14. Matz MV, Fradkov AF, Labas YA, Savitsky AP, Zaraisky AG, Markelov ML, Lukyanov SA. Fluorescent proteins from nonbioluminescent Anthozoa species. Nat Biotech. 2000;17:969-973.
15. Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev. 1999;13:1055-1066.
16. Thompson MA, Ransom DG, Pratt SJ, MacLennan H, Kieran MW, Detrich HW, Vail B, Huber TL, Paw B, Brownlie AJ, Oates AC, Fritz A, Gates MA, Amores A, Bahary N, Talbot WS, Her H, Beier DR, Postlethwait JH, Zon LI. The cloche and spadetail genes differentially affect hematopoiesis and vasculogenesis. Dev Biol. 1998;197:248-269.
17. Jain RK, Schlenger K, Höckel M, Yuan F. Quantitative angiogenesis assays: progress and problems. Nat Med. 1997;3:1203-1208.
18. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999;59:99-106.
19. Mendel DB, Schreck RE, West DC, Li G, Strawn LM, Tanciongco SS, Vasile S, Shawver LK, Cherrington JM. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin Canc Res. 2000;6: 4848-4858.
20. Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TA, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G, Cherrington JM. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 2000; 60:4152-4160.
21. Shaheen RM, Davis DW, Liu W, Zebrowski BK, Wilson MR, Bucana CD, McConkey DJ, McMahon G, Ellis LM. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res. 1999;59: 5412-5416.
22. Mendel DB, Laird AD, Smolich BD, Blake RA, Liang C, Hannah AL, Shaheen RM, Ellis LM, Weitman S, Shawver LK, Cherrington JM. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drugs. 2000;15:29-41.
23. Nasevicius A, Larson J, Ekker SC. Distinct requirements for zebrafish angiogenesis revealed by a VEGF-A morphant. Yeast. 2000;17:294-301.
24. Childs S, Chen J-N, Garrity DM, Fishman MC. Patterning of angiogenesis in the zebrafish embryo. Development. 2002;129:973-982.
25. Peterson RT, Link BA, Dowling JE, Schreiber SL. Small molecule developmental screens reveal the logic and timing of vertebrate development. Proc Natl Acad Sci U S A. 2000;97:12965-12969.